Skip to main content
Trending storyContinuously updated

Fortune: Haemanthus raised up to $20M, has patent but no CTO

1 reports1 report sources2 hours agoUpdate

Get up to speed on this story

AI Summary

Fortune reported that Haemanthus, an Austin blood-testing startup led by Billy Evans, has raised as much as $20 million and holds at least one granted Raman spectroscopy patent, but has no product or chief technology officer. The report compares the company to Theranos. The funding and patent details come from Fortune's reporting; the company has not been shown to have a working product.

AI-generated from reports · 1 hours agoUpdate

Latest updatesOct 25 20:05
Haemanthus, Billy Evans' 'Theranos 2.0' Startup, Has Patents and $20M but No Product or CTO

Report timeline

Follow the reports to understand different sides of the story.

Oct 25
  1. Fortune Term Sheet
    Haemanthus, Billy Evans' 'Theranos 2.0' Startup, Has Patents and $20M but No Product or CTO

    Haemanthus, the Austin blood-testing startup run by Billy Evans, has raised as much as $20 million and holds at least one granted Raman spectroscopy patent.

Trend for this story

Not enough continuous observation data yet; trend chart is not drawn for now.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing